Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Shareholders of Onzima Ventures (ONZ) will be breathing a sigh of relief following confirmation of the acquisition of the remaining 51% of private company N4 Pharma, and meaning that the new entity will relist on AIM. This won’t have come as a massive surprise as the company announced this proposed acquisition back in January, but some still seemed nervous as the announcement went right down to the wire in terms of Onzima either announcing such a deal (which constitutes a reverse takeover) or being booted off of AIM.
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
Search ShareProphets |
Stock market news |
Recent Comments |